147 related articles for article (PubMed ID: 35461968)
1. Population pharmacokinetics and IVIVC for mesalazine enteric-coated tablets.
Zhang Y; Wo SK; Leng W; Gao F; Yan X; Zuo Z
J Control Release; 2022 Jun; 346():275-288. PubMed ID: 35461968
[TBL] [Abstract][Full Text] [Related]
2. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac.
Kambayashi A; Blume H; Dressman J
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1337-47. PubMed ID: 24056057
[TBL] [Abstract][Full Text] [Related]
3. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS
Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538
[TBL] [Abstract][Full Text] [Related]
4. Toward Biopredictive Dissolution for Enteric Coated Dosage Forms.
Al-Gousous J; Amidon GL; Langguth P
Mol Pharm; 2016 Jun; 13(6):1927-36. PubMed ID: 27139040
[TBL] [Abstract][Full Text] [Related]
5. Targeted colonic release formulations of mesalazine - A clinical pharmaco-scintigraphic proof-of-concept study in healthy subjects and patients with mildly active ulcerative colitis.
Varum F; Thorne H; Bravo R; Gilgen D; Hartig C; Nicolas GP; Wild D; Liakoni E; Haschke M
Int J Pharm; 2022 Sep; 625():122055. PubMed ID: 35926752
[TBL] [Abstract][Full Text] [Related]
6. Mesalazine granules are superior to Eudragit-L-coated mesalazine tablets for induction of remission in distal ulcerative colitis - a pooled analysis.
Leifeld L; Pfützer R; Morgenstern J; Gibson PR; Marakhouski Y; Greinwald R; Mueller R; Kruis W
Aliment Pharmacol Ther; 2011 Nov; 34(9):1115-22. PubMed ID: 21923715
[TBL] [Abstract][Full Text] [Related]
7. Mesalazine Modified-Release Tablet in the Treatment of Ulcerative Colitis in the Active Phase: A Chinese, Multicenter, Single-Blind, Randomized Controlled Study.
Sun J; Yuan Y
Adv Ther; 2016 Mar; 33(3):400-9. PubMed ID: 26898569
[TBL] [Abstract][Full Text] [Related]
8. The influence of gastric emptying kinetics on the drug release from enteric coated pellets in fasted state: an in vitro/in vivo correlation.
Stefanič M; Locatelli I; Vrečer F; Sever T; Mrhar A; Bogataj M
Eur J Pharm Biopharm; 2012 Oct; 82(2):376-82. PubMed ID: 22884655
[TBL] [Abstract][Full Text] [Related]
9. Screening of Bioequivalent Extended-Release Formulations for Metformin by Principal Component Analysis and Convolution-Based IVIVC Approach.
Zhang Y; Liu H; Tang MJ; Ho NJ; Shek TL; Yang Z; Zuo Z
AAPS J; 2021 Mar; 23(2):38. PubMed ID: 33665728
[TBL] [Abstract][Full Text] [Related]
10. Mesalazine Modified-Release Tablet in the Treatment of Ulcerative Colitis in the Remission Phase: A Chinese, Multicenter, Single-Blind, Randomized Controlled Study.
Sun J; Yuan Y
Adv Ther; 2016 Mar; 33(3):410-22. PubMed ID: 26905266
[TBL] [Abstract][Full Text] [Related]
11. Gastrointestinal transit and release of mesalazine tablets in patients with inflammatory bowel disease.
Healey JN
Scand J Gastroenterol Suppl; 1990; 172():47-51. PubMed ID: 2353171
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.
Jantratid E; Prakongpan S; Amidon GL; Dressman JB
Clin Pharmacokinet; 2006; 45(4):385-99. PubMed ID: 16584285
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, Bioequivalence, and Safety Studies of Pantoprazole Sodium Enteric-Coated Tablets in Healthy Subjects.
Chen Z; Gan F; Rao X; Huang X; Chen H
Clin Pharmacol Drug Dev; 2021 May; 10(5):502-509. PubMed ID: 33128847
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the absorption from some commercial enteric-release theophylline products.
Upton RA; Powell JR; Guentert TW; Thiercelin JF; Sansom L; Coates PE; Riegelman S
J Pharmacokinet Biopharm; 1980 Apr; 8(2):151-64. PubMed ID: 7431220
[TBL] [Abstract][Full Text] [Related]
15. A new index, the core erosion ratio, of compression-coated timed-release tablets predicts the bioavailability of acetaminophen.
Sawada T; Sako K; Fukui M; Yokohama S; Hayashi M
Int J Pharm; 2003 Oct; 265(1-2):55-63. PubMed ID: 14522118
[TBL] [Abstract][Full Text] [Related]
16. Bioequivalence and food effect study of enteric-coated mesalazine tablets in healthy Chinese volunteers by HPLC-ESI-MS/MS.
Guo ZH; Deng Y; Cai HL; Li HD; Li ZH; Yan M; Zhang BK
Int J Clin Pharmacol Ther; 2016 Jun; 54(6):484-94. PubMed ID: 27049053
[TBL] [Abstract][Full Text] [Related]
17. A novel coating concept for ileo-colonic drug targeting: proof of concept in humans using scintigraphy.
Varum FJ; Hatton GB; Freire AC; Basit AW
Eur J Pharm Biopharm; 2013 Aug; 84(3):573-7. PubMed ID: 23348235
[TBL] [Abstract][Full Text] [Related]
18. Development of an enteric coating formulation and process for tablets primarily composed of a highly water-soluble, organic acid.
Crotts G; Sheth A; Twist J; Ghebre-Sellassie I
Eur J Pharm Biopharm; 2001 Jan; 51(1):71-6. PubMed ID: 11154906
[TBL] [Abstract][Full Text] [Related]
19. Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease.
Prakash A; Markham A
Drugs; 1999 Mar; 57(3):383-408. PubMed ID: 10193690
[TBL] [Abstract][Full Text] [Related]
20. A Biopredictive In Vitro Comparison of Oral Locally Acting Mesalazine Formulations by a Novel Dissolution Model for Assessing Intraluminal Drug Release in Individual Subjects.
Karkossa F; Klein S
J Pharm Sci; 2018 Jun; 107(6):1680-1689. PubMed ID: 29499277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
